Mizuho Reiterates Outperform Rating on Belite Bio, Inc, ADR (BLTE): "very well positioned" Mar 4, 2026 08:42AM
Belite Bio, Inc, ADR (BLTE) PT Raised to $200 at H.C. Wainwright Mar 4, 2026 06:42AM
Belite Bio, Inc, ADR (BLTE) PT Raised to $217 at Benchmark Following Business Update Mar 3, 2026 09:37AM
Belite Bio, Inc, ADR (BLTE) PT Raised to $266 at Cantor Fitzgerald After Higher WAC Announced Mar 3, 2026 07:44AM
Belite Bio (BLTE) Tops Q4 EPS by 15c Mar 2, 2026 04:27PM


Jan 28, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Jan 27, 2026 08:04AM Belite Bio completes enrollment in DRAGON II trial for Stargardt disease
Jan 26, 2026 06:12AM BofA Securities Starts Belite Bio, Inc, ADR (BLTE) at Buy
Jan 16, 2026 07:08AM Belite Bio (BLTE) Reiterated at Overweight by Cantor Fitzgerald
Jan 6, 2026 02:10AM Morgan Stanley Starts Belite Bio, Inc, ADR (BLTE) at Overweight
Dec 3, 2025 08:44AM Belite Bio, Inc, ADR (BLTE) PT Raised to $187 at Benchmark on Positive Phase 3 Dragon Trial Results
Dec 2, 2025 05:06AM Mizuho Upgrades Belite Bio, Inc, ADR (BLTE) to Outperform
Nov 24, 2025 06:12AM Cantor Fitzgerald Assumes Belite Bio, Inc, ADR (BLTE) at Overweight
Nov 20, 2025 05:36AM Mizuho Starts Belite Bio, Inc, ADR (BLTE) at Neutral
Nov 11, 2025 03:51PM Belite Bio, Inc, ADR (BLTE) PT Raised to $140 at Maxim Group
Nov 10, 2025 05:11PM Belite Bio (BLTE) Tops Q3 EPS by 22c
Nov 3, 2025 03:52AM Belite Bio receives UK regulatory nod for Stargardt disease drug application
Oct 17, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Oct 15, 2025 08:02AM Belite Bio receives China NMPA priority review for Stargardt treatment
Sep 15, 2025 07:28AM Belite Bio, Inc, ADR (BLTE) PT Lowered to $98 at H.C. Wainwright
Sep 10, 2025 08:51AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
Aug 12, 2025 09:42AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Aug 11, 2025 06:32AM Belite Bio (BLTE) Tops Q2 EPS by 8c
Jul 3, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
May 22, 2025 08:39AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
May 15, 2025 09:10AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
May 15, 2025 07:23AM Cantor Fitzgerald Reiterates Overweight Rating on Belite Bio, Inc, ADR (BLTE)
May 14, 2025 04:52PM Belite Bio (BLTE) Tops Q1 EPS by 10c
Mar 26, 2025 08:39AM Belite Bio, Inc, ADR (BLTE) PT Raised to $80 at Benchmark
Mar 18, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more
Mar 17, 2025 06:06AM Belite Bio (BLTE) Reports In-Line Q4 EPS
Jan 21, 2025 06:49AM Belite Bio, Inc, ADR (BLTE) PT Raised to $79 at Benchmark
Nov 13, 2024 06:52AM Belite Bio, Inc, ADR (BLTE) PT Raised to $100 at H.C. Wainwright
Nov 12, 2024 04:06PM Belite Bio (BLTE) Tops Q3 EPS by 1c
Sep 12, 2024 07:49AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Aug 13, 2024 04:41PM Belite Bio (BLTE) Misses Q2 EPS by 26c
Aug 13, 2024 06:43AM Belite Bio, Inc, ADR (BLTE) PT Raised to $60 at H.C. Wainwright
Aug 12, 2024 03:41AM Belite Bio, Inc (BLTE) Misses Q1 EPS by 5c